Send to

Choose Destination
Biotarget. 2018 Dec;2. pii: 20. doi: 10.21037/biotarget.2018.12.03.

From prevention to cure, repurposing anti-viral vaccines for cancer immunotherapy.

Author information

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Contributed equally

Conflict of interest statement

Conflicts of Interest: RJ Akhurst has sponsored research agreements with Pfizer Corp. and Plexxikon. RJ Akhurst is a co-inventor of US patent (No. 10.167,334) and International Patent #PCT/US2016/025802 co-owned by UCSF and Xoma; Mirza et al. Treatment of Cancer Using Inhibitors of TGF-beta and PD-1—2015 and WIPO Patent Application WO/2016/161410A2 U.S. Prov. Utility Appl. No. 62/143,016; A Mirza, O Li, R Akhurst. O Mamaї is a co-inventor of patent application WO 2018/056907 A1, Novel Target and Methodology to Inhibit Skin Inflammation and Blunt Skin Cancer Susceptibility. Owned by A*STAR (Singapore). E Dodagatta-Marri has no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center